PI
CYTK icon

PEAK6 Investments’s Cytokinetics CYTK Stock Holding History

PEAK6 Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$713K Hold
13,500
– – ﹤0.01% 2105
2024
Q2 		$731K Sell
13,500
-7,500
-36% -$453K ﹤0.01% 2035
2024
Q1 		$1.47M Buy
21,000
+1,300
+7% +$101K ﹤0.01% 1659
2023
Q4 		$1.64M Buy
+19,700
New +$713K 0.01% 1680

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PEAK6 Investments's CYTK Position: Q3 2024 in Review

PEAK6 Investments reduced its Cytokinetics (CYTK) stake by 25% in Q3 2024, selling an estimated $184K and leaving 9,730 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

PEAK6 Investments first reported a position in CYTK in Q2 2022 and has held it in 9 quarters since. The position peaked at $706K in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • PEAK6 Investments held 9,730 shares of Cytokinetics worth $514K as of Q3 2024.
  • PEAK6 Investments sold 3,300 Cytokinetics shares in Q3 2024, an estimated $184K.
  • Cytokinetics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2296 holding.
  • PEAK6 Investments first reported a position in Cytokinetics in Q2 2022 and has held it in 9 quarters since.
  • PEAK6 Investments's Cytokinetics position peaked at $706K in Q2 2024.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.